A Primer on Foreign Corrupt Practices Act and Anti-Corruption Issues for Healthcare and Life Science Companies, Part II: Establishing Compliance Controls to Minimize FCPA and Anti-Corruption Risks for Healthcare and Life Science Companies 

Wednesday, June 1, 2011 
This webinar series is brought to you by the Fraud and Abuse Practice Group, and is co-sponsored by the Healthcare Liability and Litigation (HL&L), Hospitals and Health Systems (HHS), Life Sciences, and Teaching Hospitals and Academic Medical Centers (TH/AMC) Practice Groups

Description

Part II of this series will focus on the following topics:

• Reducing bribery risks in overseas clinical research activities
• Effective compliance screening
• Selecting and recruiting physicians for clinical studies
• Working with, and monitoring, the CRO
• Managing conflict-of-interest risks
• Identifying who qualifies as a “government official” in foreign national health programs
• Identifying high-risk jurisdictions and designing specific compliance protocols for those jurisdictions
• Conducting effective due diligence screening of third parties
• Identifying local laws and customs in foreign jurisdictions
• Designing controls governing medical conferences, gifts, entertainment, travel, and advisory boards
• Monitoring and auditing interactions with third parties and foreign government officials
• Training distributors, third-party agents, and CROs on the company’s compliance program
• Conducting effective due diligence in mergers and transactions

Learn more about Part I or Part III.

Presenters

• John "Jay" S. Darden, Esquire
  Partner
  Patton Boggs LLP, Washington, DC
  
  
• John E. Kelly, Esquire
  Partner
  Fulbright & Jaworski LLP, Washington, DC

Moderator

• Carol A. Poindexter, Esquire
  Partner
  Shook Hardy & Bacon LLP, Washington, DC, and Kansas City, MO